Clinical Trial Update: Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial testing capecitabine plus pembrolizumab in triple-negative breast cancer after chemo-immunotherapy and surgery is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Xeloda (capecitabine)

Snippet

Sponsor: UNICANCER | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: RECRUITING